{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:33:16Z","timestamp":1791196396968,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,3,21]],"date-time":"2015-03-21T00:00:00Z","timestamp":1426896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00405-015-3604-y","type":"journal-article","created":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T11:10:42Z","timestamp":1426849842000},"page":"3857-3860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2"],"prefix":"10.1007","volume":"272","author":[{"given":"Said","family":"Farschtschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Kollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Dalchow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor-Felix","family":"Mautner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,21]]},"reference":[{"issue":"1","key":"3604_CR1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","volume":"26","author":"DGR Evans","year":"2005","unstructured":"Evans DGR, Moran A, King A et al (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26(1):93\u201397","journal-title":"Otol Neurotol"},{"issue":"4","key":"3604_CR2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG et al (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358\u2013367. doi: 10.1056\/NEJMoa0902579","journal-title":"N Engl J Med"},{"issue":"11","key":"3604_CR3","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/annonc\/mdq566","volume":"21","author":"V Mautner","year":"2010","unstructured":"Mautner V, Nguyen R, Knecht R et al (2010) Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 21(11):2294\u20132295. doi: 10.1093\/annonc\/mdq566","journal-title":"Ann Oncol"},{"issue":"1","key":"3604_CR4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","volume":"12","author":"V Mautner","year":"2010","unstructured":"Mautner V, Nguyen R, Kutta H et al (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12(1):14\u201318. doi: 10.1093\/neuonc\/nop010","journal-title":"Neuro Oncol"},{"issue":"1","key":"3604_CR5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S0022215111002805","volume":"126","author":"GK Eminowicz","year":"2012","unstructured":"Eminowicz GK, Raman R, Conibear J et al (2012) Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy. J Laryngol Otol 126(1):79\u201382. doi: 10.1017\/S0022215111002805","journal-title":"J Laryngol Otol"},{"issue":"6","key":"3604_CR6","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"SR Plotkin","year":"2012","unstructured":"Plotkin SR, Merker VL, Halpin C et al (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33(6):1046\u20131052. doi: 10.1097\/MAO.0b013e31825e73f5","journal-title":"Otol Neurotol"},{"issue":"3","key":"3604_CR7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0033-1338262","volume":"74","author":"AH Hawasli","year":"2013","unstructured":"Hawasli AH, Rubin JB, Tran DD et al (2013) Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base 74(3):136\u2013141. doi: 10.1055\/s-0033-1338262","journal-title":"J Neurol Surg B Skull Base"},{"issue":"12","key":"3604_CR8","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/ajmg.a.36754","volume":"164","author":"SR Plotkin","year":"2014","unstructured":"Plotkin SR, Albers AC, Babovic-Vuksanovic D et al (2014) Update from the 2013 international neurofibromatosis conference. Am J Med Genet A 164(12):2969\u20132978. doi: 10.1002\/ajmg.a.36754","journal-title":"Am J Med Genet A"},{"key":"3604_CR9","author":"MC Alanin","year":"2014","unstructured":"Alanin MC, Klausen C, Caye-Thomasen P et al (2014) The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Otorhinolaryngol. doi: 10.1007\/s00405-014-3398-3","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"6","key":"3604_CR10","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00280-014-2456-2","volume":"73","author":"KM Slusarz","year":"2014","unstructured":"Slusarz KM, Merker VL, Muzikansky A et al (2014) Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol 73(6):1197\u20131204. doi: 10.1007\/s00280-014-2456-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"3604_CR11","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","volume":"19","author":"MS Gordon","year":"2001","unstructured":"Gordon MS, Margolin K, Talpaz M et al (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19(3):843\u2013850","journal-title":"J Clin Oncol"},{"issue":"1","key":"3604_CR12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.1997.03550010065042","volume":"278","author":"DH Gutmann","year":"1997","unstructured":"Gutmann DH, Aylsworth A, Carey JC et al (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278(1):51\u201357","journal-title":"JAMA"},{"issue":"1","key":"3604_CR13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-009-9867-7","volume":"93","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Halpin C, Blakeley JO et al (2009) Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol 93(1):61\u201377. doi: 10.1007\/s11060-009-9867-7","journal-title":"J Neurooncol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-015-3604-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00405-015-3604-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-015-3604-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T18:15:59Z","timestamp":1559067359000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00405-015-3604-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,21]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["3604"],"URL":"https:\/\/doi.org\/10.1007\/s00405-015-3604-y","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,21]]}}}